{"disease":{"id":"congenital-bleeding-disorder","name":"congenital bleeding disorder"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01322620","title":"Survey Evaluating the Psychosocial Effects of Living With Haemophilia","phase":"","overall_status":"COMPLETED","enrollment_count":1236,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06574984","title":"Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01579955","title":"Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":321,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT00984126","title":"Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":214,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT01480180","title":"Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":186,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT03528551","title":"A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT02137850","title":"Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT01579968","title":"Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01333111","title":"Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT01395810","title":"Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT02035384","title":"Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A","phase":"","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01731600","title":"A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT02938585","title":"Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT00978380","title":"Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT01493778","title":"Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT03449342","title":"Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT02141074","title":"Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT01228669","title":"Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02994407","title":"Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02207218","title":"To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01489111","title":"Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT02941354","title":"Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01862367","title":"Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03196284","title":"A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT01467427","title":"Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT02490787","title":"Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT00951405","title":"Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02920398","title":"A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02541942","title":"Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT03075670","title":"A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01386528","title":"Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT03179748","title":"Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01586936","title":"Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors","phase":"","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01555749","title":"Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02670213","title":"A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01876745","title":"A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01631942","title":"A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false}],"total":37},"guidelines":[],"source":"Drug Landscape verified database"}